Fenebrutinib治疗系统性红斑狼疮的II期随机双盲安慰剂对照试验:疗效、安全性与药效学
这项II期多中心随机双盲安慰剂对照研究纳入260例中重度活动性SLE患者,评估口服高选择性BTK抑制剂fenebrutinib的疗效与安全性。第48周SRI-4应答率在150mg每日一次组为51%、200mg每日两次组为52%、安慰剂组为44%,均未达统计学显著差异。尽管显现强通路抑制证据,主要终点未达到,安全性总体可接受。
要点
- fenebrutinib 150mg每日一次与200mg每日两次组第48周SRI-4应答率分别为51%和52%,安慰剂组44%,均未达显著差异。
- BILAG-based Combined Lupus Assessment应答率三组分别为53%、42%和41%,同样无显著差异。
- 安全性总体相似,但200mg每日两次组严重不良事件更频繁。
核心结论
- fenebrutinib在活动性SLE患者中安全性可接受,但主要终点SRI-4应答未达到,尽管存在强通路抑制证据。
研究设计与样本
- II期、多中心、随机、双盲、安慰剂对照研究,纳入260例接受背景标准治疗的中重度活动性SLE患者,来自12个国家44个中心。
主要发现
- 第48周SRI-4应答率:fenebrutinib 150mg每日一次组51%(vs安慰剂P=0.37),200mg每日两次组52%(vs安慰剂P=0.34),安慰剂组44%。
- 第48周BILAG-based Combined Lupus Assessment应答率:150mg每日一次组53%(vs安慰剂P=0.086),200mg每日两次组42%(vs安慰剂P=0.879),安慰剂组41%。
- 安全性结果各组相似,但200mg每日两次组严重不良事件更频繁。
- 至第48周,fenebrutinib治疗组较安慰剂组降低BTK依赖性浆母细胞RNA特征、抗dsDNA自身抗体、总IgG和IgM水平,并升高补体C4水平。
关键数值与推荐
- 主要终点为第48周SRI-4应答率。
- 建议在第0至12周及第24至36周进行糖皮质激素减量。
临床怎么用
- 尽管fenebrutinib未达主要疗效终点,其药效学标志物变化提示BTK通路被有效抑制,可为后续SLE药物开发中靶点选择与终点设计提供参考。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter, randomized, placebo-controlled study. METHODS: Patients who had moderately to severely active SLE while receiving background standard therapy were randomized to receive placebo, fenebrutinib 150 mg once daily, or fenebrutinib 200 mg twice daily. Glucocorticoid taper was recommended from weeks 0 to 12 and from weeks 24 to 36. The primary end point was the SLE Responder Index 4 (SRI-4) response at week 48. RESULTS: Patients (n = 260) were enrolled from 44 sites in 12 countries, with the majority from Latin America, the US, and Western Europe. The SRI-4 response rates at week 48 were 51% for fenebrutinib 150 mg once daily (P = 0.37 versus placebo), 52% for fenebrutinib 200 mg twice daily (P = 0.34 versus placebo), and 44% for placebo. British Isles Lupus Assessment Group-based Combined Lupus Assessment response rates at week 48 were 53% for fenebrutinib 150 mg once daily (P = 0.086 versus placebo), 42% for fenebrutinib 200 mg twice daily (P = 0.879 versus placebo), and 41% for placebo. Safety results were similar across all arms, although serious adverse events were more frequent with fenebrutinib 200 mg twice daily. By week 48, patients treated with fenebrutinib had reduced levels of a BTK-dependent plasmablast RNA signature, anti-double-stranded DNA autoantibodies, total IgG, and IgM, as well as increased complement C4 levels, all relative to placebo. CONCLUSION: While fenebrutinib had an acceptable safety profile, the primary end point, SRI-4 response, was not met despite evidence of strong pathway inhibition.
引用
- Isenberg D, Furie R, Jones NS, et al. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021. PMID: 34042314. doi:10.1002/art.41811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。